TRAF1 and breast cancer: And TRAF1 may have a pro-apoptotic and anti-mitotic effects.[13,14] The researches of reported bioinformatics showed the expression level of TYK2, as one of prognostic biomarkers, was higher in tumor tissues than in normal tissues in breast cancer and hepatocellular carcinoma.[15,16] Besides, MET was also regarded as a potential target across all Papillary Renal Cell Carcinomas.[17,18] Consistently, our results also observed that the expression of TRAF1 and TYK2 were low, the expression of MET was high in pancreatic cancer.